Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | MDM2 proto-oncogene, E3 ubiquitin protein ligase | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium vivax | replication protein A1, large subunit, putative | 0.0059 | 0.4181 | 1 |
Loa Loa (eye worm) | BRCA2 repeat family protein | 0.0025 | 0.1082 | 0.1082 |
Echinococcus granulosus | replication protein A 70 kDa DNA binding | 0.0123 | 1 | 1 |
Chlamydia trachomatis | DNA topoisomerase I | 0.0013 | 0 | 0.5 |
Toxoplasma gondii | replication factor-a protein 1 (rpa1) subfamily protein | 0.0059 | 0.4181 | 1 |
Echinococcus multilocularis | replication protein A 70 kDa DNA binding | 0.0123 | 1 | 1 |
Brugia malayi | BRCA2 repeat family protein | 0.0025 | 0.1082 | 0.1082 |
Entamoeba histolytica | replication factor A protein 1, putative | 0.0053 | 0.363 | 0.5 |
Trichomonas vaginalis | replication factor A 1, rfa1, putative | 0.0117 | 0.9449 | 0.9449 |
Toxoplasma gondii | OB-fold nucleic acid binding domain-containing protein | 0.0031 | 0.1633 | 0.3905 |
Schistosoma mansoni | replication factor A 1 rfa1 | 0.0123 | 1 | 1 |
Leishmania major | replication factor A, 51kDa subunit, putative | 0.0059 | 0.4181 | 0.5 |
Plasmodium falciparum | replication protein A1, large subunit | 0.0059 | 0.4181 | 1 |
Trypanosoma brucei | Replication factor A protein 1 | 0.0059 | 0.4181 | 0.5 |
Trichomonas vaginalis | replication factor A 1, rfa1, putative | 0.0123 | 1 | 1 |
Loa Loa (eye worm) | replication factor A 73 kDa subunit | 0.0123 | 1 | 1 |
Trypanosoma cruzi | Replication factor A protein 1 | 0.0059 | 0.4181 | 0.5 |
Chlamydia trachomatis | SWIB complex protein | 0.0013 | 0 | 0.5 |
Trichomonas vaginalis | replication factor A 1, rfa1, putative | 0.0123 | 1 | 1 |
Trichomonas vaginalis | replication factor A 1, rfa1, putative | 0.0059 | 0.4181 | 0.4181 |
Giardia lamblia | Hypothetical protein | 0.0018 | 0.0459 | 0.5 |
Onchocerca volvulus | Putative replication factor A 73 kDa subunit | 0.011 | 0.8826 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | < 1000 nM | BindingDB_Patents: Fluorescence-Polarization Binding Assay. The binding affinity of the MDM2 inhibitors was determined using an optimized, sensitive and quantitative fluorescence polarization-based (FP-based) binding assay using a recombinant human His-tagged MDM2 protein (residues 1-118) and a fluorescently tagged p53-based peptide.The design of the fluorescence probe was based upon a previously reported high-affinity p53-based peptidomimetic compound (5-FAM-beta Ala-beta Ala-Phe-Met-Aib-pTyr-(6-Cl-LTrp)-Glu-Ac3c-Leu-Asn-NH2 (SEQ ID NO: 1)) Garcia-Echeverria et al., J. Med. Chem. 43: 3205-3208 (2000)). This tagged peptide is called PMDM6-F. The Kd value of PMDM6-F with the recombinant MDM2 protein was determined from the saturation curve. MDM2 protein was serially double diluted in a Dynex 96-well, black, round-bottom plate, and the PMDM6-F peptide was added at 1 nM concentration. The assay was performed in the buffer: 100 mM potassium phosphate, pH 7.5; 100 ug/mL bovine gamma globulin; 0.02% sodium azide, 0.01% Triton X-100). | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.